EOC, an Eddingpharm Spin-out, Closes $32 Million B Round for Oncology Assets

EOC Pharma Group of Shanghai closed a $32 million B funding round. EOC, a spin-out  from Eddingpharm, in-licenses rights to develop, manufacture and market oncology assets from global pharmas. Eddingpharm in-licenses only marketing and commercialization rights for China , while EOC develops clinical-stage assets from global pharmas. So far, EOC has in-licensed a pipeline of six candidates, which it hopes will prove to be first-in-class or best-in-class. The pipeline consists of mid- and late-stage clinical products; EOC hopes to in-license additional late-stage clinical oncology assets. More details... Share this with colleagues: // //